PURPOSE
To evaluate retrospectively the incidence, predictive factors, and management of acute pancreatitis which develops following placement of duodenal stents in patients with malignant gastroduodenal obstruction.
MATERIALS AND METHODS
Among 242 patients with symptomatic malignant gastroduodenal obstruction successfully treated with duodenal stent placement, acute pancreatitis occurred in 10 patients (4.1%) at 1-7 days after stent placement. Univariate and multivariate analyses were performed to evaluate factors predictive of acute pancreatitis. Management of acute pancreatitis was also evaluated.
RESULTS
Ten patients with acute pancreatitis presented with abdominal pain and distention with vomiting at 1-7 days after stent placement, and seven patients developed acute jaundice. Pancreatitis resolved in four patients with a regime of fasting and intravenous nutrition. The remaining six cases were managed with percutaneous transhepatic cholangiography and drain (PTCD) placement. Univariate analysis showed that acute pancreatitis was associated with stent location in the descending duodenum (P = 0.001) and with stents bridging the duodenal papilla (P < 0.001). Multivariate analysis demonstrated that the presence of a stent bridging the duodenal papilla (odds ratio, 18.48; 95% confidence interval, 2.298-148.48; P = 0.006) was an independent predictor of acute pancreatitis.
CONCLUSION
Acute pancreatitis is an uncommon early complication of duodenal stent placement in patients with malignant gastroduodenal obstruction. In this group of patients, acute pancreatitis was associated with stent location in the descending duodenum and occurred in patients with stents bridging the duodenal papilla; the latter may be the most important predictor of acute pancreatitis. Jaundice can be managed conservatively or with PTCD.
radiologist and an endoscopist under fluoroscopic guidance. Details of the stent placement technique are described elsewhere (4, 6, 19, 20) (Fig. 2a  and 2b ).
All patients underwent plain abdominal radiography, clinical examination, contrast medium radiographic study, and/or endoscopy between 1 and 7 days after stent placement to confirm the position and patency of the stent and to evaluate possible complications. For patients with abdominal pain, vomiting, or jaundice post-stent placement, laboratory examinations, including blood count, electrolytes, clotting time, liver and renal function, and blood, urine, and pancreatic amylase were performed. A contrast-medium study and endoscopy were performed at one month after stent placement to detect the presence of delayed complications, such as stent migration and obstruction. Further follow-up contrast-medium studies and endoscopy were performed only for those patients with recurrent symptoms.
Variables
The variables analyzed were age at the time of operation, sex, type of malignancy (gastric, duodenal, and gallbladder cancer and metastasis), length of obstruction, location of obstruction (descending duodenum [ Fig. 2a ] or non-descending duodenum), degree of obstruction (moderate or severe), number of stents, radiotherapy (administered or not before stent placement), chemotherapy (administered or not before stent placement), and stent bridging the duodenal papilla (yes or no; Fig. 2b ). We excluded pancreatic cancer from this study because pancreatic cancer itself can cause acute pancreatitis, and it can therefore be difficult to distinguish acute pancreatitis resulting from pancreatic cancer from that secondary to the presence of a duodenal stent.
Definition and analysis of data
Acute pancreatitis was defined as acute abdominal pain, vomiting with hemodiastase, and/or increase in urinary amylase and pancreatic enlargement between 1 and 7 days after stent placement. Data are presented as the mean±standard deviation (SD). Univariate analysis was performed to compare variables between the groups with and without acute pancreatitis. The Mann-Whitney U test was used to compare continuous variables, and Fisher's exact test was used for categorical variables.
A multivariate logistic regression model with forward stepwise selection was planned for finding independent predictive factors associated with acute pancreatitis. Only variables with P < 0.2 on univariate analysis (MannWhitney U test or Fisher's exact test) were entered into the multivariate logistic regression model. Statistical analyses were performed with a commercially available software (Statistical Package for Social Sciences, version of these patients were male, and three were female (mean age, 64.50±10.93 years; age range, 45-81 years). No acute pancreatitis event was identified in any of the 10 patients by medical history or CT examination prior to stent placement.
Stent placement and follow-up
The duodenal stent (Micro-Tech, Nanjing, China) was woven from a single thread of 0.16-mm-diameter highly elastic nitinol wire. The stent was in a tubular configuration with a drum structure at the proximal and distal ends, as shown in Fig. 1 . The body of the device was 18-22 mm in diameter when fully expanded and 60-160 mm in length. The drum structure at the proximal and distal ends of the device was 5 mm wider than the body and 10 mm in length. For implantation under fluoroscopic or endoscopic guidance, the stent was delivered in a compressed form inside an introducer sheath with a diameter of 16 F. All procedures were performed by an interventional 13.0, SPSS Inc., Chicago, Illinois, USA). A P value ≤ 0.05 was considered statistically significant.
Results

Characteristics and management of acute pancreatitis
All patients with acute pancreatitis initially presented with abdominal pain and distention with vomiting after stent placement. Seven patients developed acute jaundice one week after the procedure due to misdiagnosis of the presenting abdominal pain. Additionally, CT imaging demonstrated pancreatic enlargement or edema in all patients (Fig. 2c) .
Acute pancreatitis was observed between one and three days after the procedure in three cases, and this resolved with fasting, intravenous nutrition, and appropriate antibiotics for seven days. The remaining seven cases of acute pancreatitis were not diagnosed until the occurrence of acute jaundice. Six patients were managed with percutaneous transhepatic cholangiography and drain (PTCD) placement, and one patient was treated conservatively. There was no mortality in the study.
Predictive factors of acute pancreatitis
Ten variables were compared between the two groups (acute pancreatitis and no acute pancreatitis) in univariate analysis. The results are presented in Table 2 . Univariate analysis revealed that acute pancreatitis was associated with stent location in the descending duodenum (P = 0.001) and with a stent bridging the duodenal papilla (P < 0.001) ( Table 2 ). Other variables showed no significant difference between the two groups with acute pancreatitis.
Two variables with P < 0.2 at univariate analysis were entered into the multiple logistic regression model: location of obstruction and stent bridging the duodenal papilla. Multivariate analysis confirmed that a stent bridging the duodenal papilla (odds ratio [OR], 18.48; 95% confidence interval [CI], 2.298-148.48; P = 0.006) was an independent predictor of acute pancreatitis (Table 3) .
Discussion
The results demonstrate that acute pancreatitis is very rare following stent placement, which occurred with a frequency of 4.1% (10/242) and tended to occur early. In our multiple logistic regression analysis, a stent bridging the duodenal papilla (OR, 18.48; P = 0.006) was a significant predictor of the development of acute pancreatitis. On the other hand, age, sex, type of malignancy, length, location, and degree of obstruction, number of stents, radiation, and chemotherapy all showed no association.
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Two main factors were associated with the occurrence of acute pancreatitis after duodenal stent placement. One was related to closure of the orifice of the duodenal papilla, which may have directly caused an increase in pressure in the pancreatic duct.
The duodenal papilla was compressed or irritated by the stent, which led to acute edema or shrinkage of the orifice of the duodenal papilla and subsequently to an increase in pressure in the duct. Another reason was that the blood supply to the pancreas decreased as a result of compression of the peripheral vessels when the stent was placed in the descending duodenum, leading to acute pancreatitis. Additionally, covered duodenal stents may be another important risk factor for acute pancreatitis because they can occlude the orifice of the duodenal papilla, which may directly cause a pressure increase in the pancreatic duct (2) . In this study, bare duodenal stents were used in all patients, and thus this factor was excluded.
Although acute pancreatitis is not an unexpected complication of this procedure (2, 6, 18, 21) , to the best of our knowledge, there have been no previous reports of acute pancreatitis, which develops following placement of stents in the descending duodenum. There are several explanations for this lack of reports. First, it is easy to misdiagnose abdominal pain and vomiting due to the lack of specific symptoms, which generally leads to conservative treatment. When abdominal pain and vomiting occur, it is often ascribed to reobstruction or pain resulting from stent compression rather than to acute pancreatitis. Second, when the covered stent is applied to the duodenal area, PTCD is usually performed before stent placement, thus preventing the occurrence of acute pancreatitis (4, 22) .
This study had a number of limitations. First, it was a retrospective analysis. Second, the sample size of the study population with acute pancreatitis may have been too small to detect real differences between the two groups (type II error). Furthermore, we excluded pancreatic cancer from this study to rule out the possibility that acute pancreatitis might have resulted from the cancer itself. As a result, our results may not be generally applicable.
As a conclusion, acute pancreatitis was an uncommon early complication of duodenal stent placement in patients with malignant gastroduodenal obstruction. Acute pancreatitis was associated with stent location in the descending duodenum and occurred in patients with a stent bridging the duodenal papilla, with the latter identified as an independent predictor of acute pancreatitis. Acute pancreatitis can be managed conservatively or by PTCD when acute jaundice develops.
For patients who present with severe or worsening abdominal pain and fever or vomiting following stent placement for gastric outlet or duodenal stenosis, acute pancreatitis should be considered.
